Body As A Whole	
Cardiovascular system	
Digestive system	
•• • • • • •	
مریک از میکند از میکند میکند میکند میکند و این میکند با این میکند بیک از میکند میکند و این میکند و این میکند میکند و این میکند و ا این میکند و این	al
¹ στη	
r	
lemic and lymphatic system	
Anemia, ecchymosis, leukocytosis, polycythemia.	
letabolic and nutritional	
Ikaline phosphatase increased, ypercholesteremia,	×, .
lusculoskeletal system	
rthritis, arthrosis,	
ramps, myopathy	

DOCKET ALARM Find authenticated court documents without watermarks at <u>docketalarm.com</u>.

,

Δ

Α

Nervous system	
Agitation,	an teachean air an an Starbard an Starb
	en syntyche, same a sen an an
stupor.	
Respiratory system	
	epistaxis, hiccup,
Skin and appendages	
	rash,
Special senses	
	tangkan-kepaté ang pangkan di Sangkan di Sang
taste loss,	
Urogenital system	
albuminuria, menorrhagia,	المراجعة المراجع المراجعة الم فقد المراجع المراجعة
papanicolau <u>Papanicolau</u> smear suspicious, polyuria, pro	static disorder, testis
The second s	
	NEW OF COMPANY OF A CONTRACTOR OF C
	an manan sa
	Not seen the constant and a second of the second
Construction of the second se	¹ Constructed School and the rest of some state of the School School and the rest of the source

DOCKE. R Μ Find authenticated court documents without watermarks at docketalarm.com.

Review and Evaluation of Clinical Data

NDA (Serial Number)	21196 (000)	
Sponsor:	Orphan Medical, Inc.	
Drug:	Xyrem	
Proposed Indication:	Narcolepsy	
Material Submitted:	Labeling Review	
Correspondence Date:	9/30/00	
Date Received / Agency:	10/3/00	
Date Review Completed	6/14/01	
Reviewer:	Ranjit B. Mani, M.D.	•

Background

This submission contains an original New Drug Application for Xyrem® (scdium oxybate; γ-hydroxybutyrate) oral solution.

This document reviews the sponsor's proposed labeling as proposed in the original application and as modified in a further submission dated 12/16/00.

The safety and efficacy data in this application have each been reviewed by me in separate applications.

The sponsor's draft labeling, as edited by me, is presented below. My editing and review of the label have been confined to sections subsumed under my clinical reviews

Edited Draft Labeling

Draft Professional Insert (December 15, 2000 Version) Modified to include information from Trial OMC-SXB-21 and OMC-SXB-20

 R_x only

CIII

Xyrem[®] (sodium oxybate) oral solution

DESCRIPTION

Xyrem (sodium oxybate) is a neuroactive agent with effects on sleep architecture that include increased slow wave sleep, increased delta power, and decreased

Ranjit B. Mani, MD, HFD-120 Medical Review	Page 2 of 35
NDA 21196 (000), Xyrem, Orphan Medical, Inc.	6/14/01

nocturnal awakenings. Xyrem is intended for oral administration. The chemical name for sodium oxybate is gamma-hydroxybutyric acid (GHB), sodium. The molecular formula is $NaC_4H_7O_3$ and the molecular weight is 126.1 grams/mole. The chemical structure is:

Sodium oxybate is a white to off-white, crystalline powder that is very soluble in aqueous solutions. Xyrem contains 500 mg of sodium oxybate per milliliter of USP purified water, neutralized to pH 7.5 with malic acid.

والمحافظ والمستحد المنافع المنافع المحافظ المحافظ المحافظ المحافظ

CLINICAL PHARMACOLOGY

Mechanism of Action

Δ

DOCKET Find authenticated court documents without watermarks at docketalarm.com.

Ranjit B. Mani, MD, HFD-120 Medical Review NDA 21196 (000), Xyrem, Orphan Medical, Inc.		Paç	e 3 of _{6/1}	
			۵۳ که از است. او	
	وورو و معاون می وارد از بیش و با با با با با و اور اور اور و و و مراد می و و و و و و و و و و و و و و و و و و	ويون پېرېيىلىكىنى ئەرىكىيىلىكى ئېرىكىنىڭ مىرىنىڭ ئىرىنىڭ بىرىنىڭ بىرىنىڭ جەنبىيە بىرىنىكىيىلىكى ئېرىنىڭ ئىلىرىد	nene an	
	والمحفور والمحفوم ومعارب والمعارية والمحاولة والمحاولة والمحاولة والمحاولة والمحاولة والمحاولة والمحاولة والمح	ĸĸĸĸĸŶĸĊĸĸŦŦĸĸĬĊġĊŦĸĸŦŦŶŶĊĊŶĊĸġĦĊŎĬŎŎĬŎĬŎĸŎŎĸĊŦĬŎſĊĬĸĬĊŎĿŎġĿŢĴŎŦĸĸŔŎţŎĿŎŎŢŎŎĿŎŎĿŎĬĬŎŎĬŎĸŎĸŎŎŢŎĸ	₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩	
میں ایک میں اور				
	ومراولا المحاصرين والمراجع ومواجع والمراجع ومراجع ومحاصر والمراجع ومحاصر والمراجع والمحاصر والمراجع والمحاص وال	يەر ئەھەر يەھە يەر بەر ئەر ئەر ئەر ئەلەر مەھەر بەر ئەر ئەر ئەر بەر يەر مەھەر تەر ئەر بەر بەر بەر بەر بەر يەر بە ئەر ئەھەر يەر بەر بەر بەر بەر ئەر ئەر ئەر ئەر ئەر ئەر ئەر ئەر ئەر بەر يەر ئەر ئەر ئەر ئەر ئەر ئەر ئەر ئەر ئەر ئ	ምን ትር አልነቆጅ የአስጥሚኒ በንቅ ንም "የተቆርቀ የመንሰር ሃጋር ምንያቸው" ጊዜ አንድር መንካታቸው መረት ግራ የቆማ መንካት መንካት የመንሰር እና እ	
Contract of the second s	har			
	na manana manang ang ang ang ang ang ang ang ang an	ግ ዓን ይኖሩ ሰባን ይማንተላቂ ናቸው አንድር አመንግስ እርገኛ በአንድር የመቀታ ያያለው ያደረው ማቅርት በአንድር የአንድር ማስት ትኛ አንድት መንግስ ያያለው ያያለው ያንድር ያ	₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩	
-قىلغەرىيى سەرىيەرىيى	می از می از این است به می وجود و سال و اینون از این	den Marken en e	ዺጚዀኯዸዸኯኯጟጟጞጟዸዾኯቒፙቒኯጚጟጟኯኯዸኯጚኇዾዾዀጚጞጞዀኯ፟ኯኯኯዸዾኯጚጟቒቔኯዸኇፙ፼ኯኇቜዀዸኯቘኯዸጚጟጟዸኯጚጚኯኯፙኯኊጚ	beau and a
and a second	يون من المراجع	nenne (m. 1997). The Constant of Constant of Constant (Station of Constant) and Constant of Constant of Constant	₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩	
The second secon		۵۰۰۰۰ که ۲۰۵۳ می بوده که ۲۰۵۹ می این و کورو کورو می این می بوده و می بوده این می بوده این می بوده این می بوده ا ۱۹۹۸ می بوده می بوده این می بوده می بوده می بوده و کورو کورو می بوده می بوده می بوده می بوده این می بوده می بوده	and the set of the set	
Pharmaco	kinetics and N	Metabolism		-
				`
Absorption	1			
· •				
	abs	orbed following oral adm	inistration. The average	بر
is	neak plasma c	NARCANTRATIAN		
	peak plasma c	concentration		•
	peak plasma c		-	
	peak plasma c		-	
	peak plasma c			
	peak plasma c			
Administra	tion of	after a high f	at meal resulted in a	verag
Administra T _{max} increa	tion of 0.75	after a high f hr to 2.0 hr and	at meal resulted in a	verag
Administra T _{max} increa	tion of 0.75	after a high f	at meal resulted in a	verag
Administra T _{max} increa	tion of 0.75	after a high f hr to 2.0 hr and re hic exposure (AUC) by 37	at meal resulted in — a eductions in peak plasma 7%.	verag
Administra T _{max} increa	tion of 0.75	after a high f hr to 2.0 hr and re hic exposure (AUC) by 37	at meal resulted in a	verag
Administra T _{max} increa (C _{max}) of 58	tion of sing from 0.75 8% and system	after a high f hr to 2.0 hr and re hic exposure (AUC) by 37	at meal resulted in — a eductions in peak plasma 7%.	verag
Administra T _{max} increa	tion of sing from 0.75 8% and system	after a high f hr to 2.0 hr and re hic exposure (AUC) by 37	at meal resulted in — a eductions in peak plasma 7%.	verag

ţ

. . .

DOCKET A L A R M Find authenticated court documents without watermarks at <u>docketalarm.com</u>.

DOCKET A L A R M



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.